Kindred Biosciences Announces Positive Results from Pilot Field Effectiveness Study of epoCat™ for the Management of Non-Regenerative Anemia in Cats and Availability of Mirataz® at Banfield Pet Hospital

SAN FRANCISCO, CA (January 14, 2019) Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced positive topline results from its pilot field effectiveness study of epoCat (KIND-510a), a long-acting feline recombinant erythropoietin that is being developed for the management of anemia in cats. In […]

Kindred Biosciences Announces Third Quarter 2018 Financial Results

San Francisco, CA (November 7, 2018) Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the third quarter ended September 30, 2018 and provided updates on its programs. For the third quarter 2018, KindredBio reported net product revenues of $0.6 million and […]

Kindred Biosciences Announces Positive Results from Pilot Effectiveness Study of its Fully Caninized IL-31 Antibody for the Treatment of Atopic Dermatitis in Dogs and Issuance of U.S. Patent

Statistically significant reduction in pruritus versus placebo was achieved across all dose groups. Canine atopic dermatitis is a large and growing market, and KindredBio has a broad portfolio of biologics in development to treat this condition. San Francisco, CA (October 30, 2018) — Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving […]

Kindred Biosciences to Announce Third Quarter 2018 Financial Results

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on Wednesday, November 7, 2018 San Francisco, CA (October 24, 2018) Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will release its third quarter […]

Kindred Biosciences Elects Denise Bevers to its Board of Directors and Promotes Her to President

San Francisco, CA (October 23, 2018) — Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced that Denise Bevers, Co-Founder and Chief Operating Officer of KindredBio, has been elected to its Board of Directors and promoted to President. Since co-founding KindredBio in 2012, Ms. […]